Raloxifene (Ral) v placebo for postmenopausal osteoporosis with or without prior hormone therapy (HT) use at 4 years*
| Outcomes | Population | Comparisons | Event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | |||||
| New vertebral fractures | Women with prior HT use | Ral, 60 mg/d, v placebo | 5.7% v 12.4% | 54% (33 to 68) | 15 (11 to 28) |
| Women without prior HT use | 9% v 12.7% | 29% (13 to 42) | 28 (18 to 64) | ||
| Breast cancer | Women with prior HT use | Ral, 60 or 120 mg/d, v placebo | 0.73% v 2.3% | 68% (34 to 85) | 64 (34 to 182) |
| Women without prior use | 0.64% v 1.47% | 56% (25 to 75) | 121 (66 to 352) | ||